VAERS Explorer
Back to explore

Report #2888908

Received Mar 13, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
NJ
Recovered
Not recovered
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
COVID19COVID19 (COVID19 (PFIZER-BIONTECH))PFIZER\BIONTECHUNK——

Symptoms (2)

EczemaImmune system disorder

Symptom narrative

patient developed a non-serious immune system being messed up got "wrecked (immune system disorder; "still experiencing "very bad eczema"; This is a spontaneous report received from an Other HCP. A 63-year-old male patient received BNT162b2 (BNT162B2 NOS), in 2024 as dose number unknown, singlen (Batch/Lot number: unknown) for covid-19 immunisation; dupilumab (DUPILUMAB), in 2023 as 300 mg (qow (every 2 weeks)) (Lot number: 5F749A, Expiration Date: 31Jan2028) for eczema. The patient's relevant medical history included: "Eczema", start date: 2023 (ongoing). The patient's concomitant medications were not reported. The following information was reported: IMMUNE SYSTEM DISORDER (non-serious), outcome "unknown", described as "patient developed a non-serious immune system being messed up got "wrecked (immune system disorder"; ECZEMA (non-serious), outcome "not recovered", described as ""still experiencing "very bad eczema"". The action taken for dupilumab was unknown. Additional information: The patient, whose immune system had been compromised, got wrecked and still experienced very bad eczema due to the immune system being compromised while receiving the COVID-19 vaccine and while being treated with DUPILUMAB delivered via Dupixent single-dose pre-filled pen. In 2024, the patient received a dose of the suspect COVID-19 vaccine not produced by Sanofi Pasteur, with the lot number not reported, via an unknown route and administration site. On an unknown date, the patient developed a non-serious immune system disorder described as "wrecked" (unknown latency) following the first dose of DUPILUMAB. On an unknown date, the patient developed a event of still experiencing very bad eczema due to the compromised immune system (therapeutic response decreased, unknown latency) following the first dose of DUPILUMAB. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.

Current illness

Eczema